Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Jun;91(6):604–611. doi: 10.1111/j.1349-7006.2000.tb00988.x

Spicamycin and KRN5500 Induce Apoptosis in Myeloid and Lymphoid Cell Lines with Down‐regulation of Bcl‐2 Expression and Modulation of Promyelocytic Leukemia Protein

Wen Jie Zhang 1, Kazunori Ohnishi 1, Hitoshi Yoshida 1, Ling Pan 1, Lola Maksumova 1, Farkhad Muratkhodjaev 1, Jian Min Luo 1, Kazuyuki Shigeno 1, Shinya Fujisawa 1, Kensuke Naito 1, Satoki Nakamura 1, Kaori Shinjo 1, Akihiro Takeshita 1, Ryuzo Ohno ✉
PMCID: PMC5926402  PMID: 10874212

Abstract

Spicamycin is a potent inducer of differentiation of human myeloid leukemia cells (HL‐60) and murine myeloid leukemia cells (M1). One of the spicamycin derivatives, KRN5500, shows a broad spectrum of antitumor activity against human tumor xenografts in nude mice. In this study, we first investigated the differentiation efficacy of spicamycin and KRN5500 in HL‐60 and acute promyelocytic leukemia cell line, NB4, and found that low concentrations of both compounds induced differentiation to a small extent in both cell lines, but markedly induced apoptosis in NB4 cells. Further investigation in a myeloid leukemia cell line, NKM‐1, a lymphoma cell line, Daudi, and multiple myeloma cell line, NOP‐1, showed that high concentrations of both compounds also induced apoptosis in these cells. The 50% inhibitory concentration (IC50) determined by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay showed that myeloid cells were more sensitive to both compounds than lymphoid cells, and spicamycin was more potent than KRN5500. Western blot analysis of Bcl‐2, Bcl‐xL and Bax expression and immunofluorescence analysis of promyelocytic leukemia (PML) protein indicated that apoptosis induced by spicamycin and KRN5500 was associated with down‐regulation of Bcl‐2 expression and modulation of PML protein. Thus, spicamycin and KRN5500 may be useful for the treatment of myeloid and lymphoid neoplasms.

Keywords: Spicamycin, KRN5500, Apoptosis, Bcl‐2, PML

Full Text

The Full Text of this article is available as a PDF (895.6 KB).

REFERENCES

  • 1. ) Hayakawa , Y. , Nakagawa , M. , Kawai , H. , Tanabe , K. , Nakayama , H. S. H. , Shimazu , A. , Seto , H. and Otake , N.Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL‐60 human promyelocytic leukemia cells . J. Antibiot. (Tokyo) , 36 , 934 – 937 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Hayakawa , Y. , Nakagawa , M. , Kawai , H. , Tanabe , K. , Nakayama , H. , Shimazu , A. , Seto , H. and Otake , N.Spicamycin, a new differentiation inducer of mouse myeloid leukemia cells (M1) and human promyelocytic leukemia cells (HL‐60) . Agric. Biol. Chem. , 49 , 2685 – 2691 ( 1985. ). [Google Scholar]
  • 3. ) Kamishohara , M. , Kawai , H. , Sakai , T. , Isoe , T. , Hasegawa , K. , Mochizuki , J. , Uchida , T. , Kataoka , S. , Yamaki , H. , Tsuruo , T. and Otake , N.Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells . Oncol. Res. , 6 , 383 – 390 ( 1994. ). [PubMed] [Google Scholar]
  • 4. ) Kamishohara , M. , Kawai , H. , Sakai , T. , Uchida , T. , Tsuruo , T. and Otake , N.Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer‐producing tissue polypeptide antigen . Cancer Chemother. Pharmacol. , 38 , 495 – 498 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Kawai , H.Protein synthesis inhibitor—antitumor activity and mode of action of KRN 5500 . Cancer Chemother. , 24 , 1571 – 1577 ( 1997. ). ( in Japanese ). [PubMed] [Google Scholar]
  • 6. ) Matsumura , Y. , Kamiya , Y. , Yamamoto , N. , Ono , H. , Shirao , K. , Kondo , H. , Tanigawara , Y. , Tamura , T. and Shimada , Y.A phase I study of KRN5500 in patients with refractory solid tumors (stomach, colon, lung) . Clin. Pharm. , 18 , 219a ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Kataoka , T. , Morishita , Y. , Ogura , M. , Morishima , Y. , Towatari , M. , Kato , Y. , Inoue , H. and Saito , H.A novel human myeloid leukemia cell line, NKM‐1, coexpressing granulocyte colony‐stimulating factor receptors and macrophage colony‐stimulating factor receptors . Cancer Res. , 50 , 7703 – 7709 ( 1990. ). [PubMed] [Google Scholar]
  • 8. ) Ogura , M. , Ueda , R. , Takeo , T. , Morishima , T. , Hirabayashi , N. and Saito , H.Establishment and characterization of a novel human IgA, K myeloma cell line (NOP‐1) with CD4 antigen in vitro and vivo . Blood , 74 , 81a ( 1990. ). [Google Scholar]
  • 9. ) Lanotte , M. , Martin‐Thouvenin , V. , Najman , S. , Balerini , P. , Valensi , F. and Berger , R.NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3) . Blood , 77 , 1080 – 1086 ( 1991. ). [PubMed] [Google Scholar]
  • 10. ) Dalton , W. T. , Jr. , Ahearn , M. J. , McCredie , K. B. , Freireich , E. J. , Stass , S. A. and Trujillo , J. M.HL‐60 cell line was derived from a patient with FAB‐M2 and not FABM3 . Blood , 71 , 242 – 247 ( 1988. ). [PubMed] [Google Scholar]
  • 11. ) Klein , E. , Klein , G. , Nadkarni , J. S. , Nadkarni , J. J. , Wigzell , H. and Clifford , P.Surface IgM‐kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines . Cancer Res. , 28 , 1300 – 1310 ( 1968. ). [PubMed] [Google Scholar]
  • 12. ) Zhang , W. , Ohnishi , K. , Shigeno , K. , Fujisawa , S. , Naito , K. , Nakamura , S. , Takeshita , K. , Takeshita , A. and Ohno , R.The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms . Leukemia , 12 , 1383 – 1391 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Steinkamp , J. A. , Wilson , J. S. , Saunders , G. C. and Stewart , C. C.Phagocytosis: flow cytometric quantitation with fluorescent microspheres . Science , 215 , 64 – 66 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Lee , Y. S. , Nishio , K. , Ogasawara , H. , Funayama , Y. , Ohira , T. and Saijo , N.In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines . Cancer Res. , 55 , 1075 – 1079 ( 1995. ). [PubMed] [Google Scholar]
  • 15. ) Lowe , S. W.Cancer therapy and p53 . Curr. Opin. Oncol. , 7 , 547 – 553 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Peter , M. E. and Krammer , P. H.Mechanisms of CD95 (APO‐1/Fas)‐mediated apoptosis . Curr. Opin. Immunol. , 10 , 545 – 551 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Reed , J. C.Double identity for proteins of the Bcl‐2 family . Nature , 387 , 773 – 776 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Hockenbery , D. M. , Oltvai , Z. N. , Yin , X. M. , Milliman , C. L. and Korsmeyer , S. J.Bcl‐2 functions in an antioxidant pathway to prevent apoptosis . Cell , 75 , 241 – 251 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) de The , H. , Chomienne , C. , Lanotte , M. , Degos , L. and Dejean , A.The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus . Nature , 347 , 558 – 561 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Grignani , F. , Testa , U. , Rogaia , D. , Ferrucci , P. F. , Samoggia , P. , Pinto , A. , Aldinucci , D. , Gelmetti , V. , Fagioli , M. , Alcalay , M. , Seeler , J. , Grignani , F. , Nicolitti , I. , Peschle , C. and Pelicci , P. P.Effects on differentiation by the promyelocytic leukemia PML/RARA protein depend on the fusion of the PML protein dimerization and RARA DNA binding domains . EMBO J. , 15 , 4949 – 4958 ( 1996. ). [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Yoshida , H. , Kitamura , K. , Tanaka , K. , Omura , S. , Miyazaki , T. , Hachiya , T. , Ohno , R. and Naoe , T.Accelerated degradation of PML‐retinoic acid receptor α (PMLRARA) oncoprotein by all‐trans‐retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway . Cancer Res. , 56 , 2945 – 2948 ( 1996. ). [PubMed] [Google Scholar]
  • 22. ) Chen , G. Q. , Zhu , J. , Shi , X. G. , Ni , J. H. , Zhong , H. J. , Si , G. Y. , Jin , X. L. , Tang , W. , Li , X. S. , Xong , S. M. , Shen , Z. X. , Sun , G. L. , Ma , J. , Zhang , P. , Zhang , T. D. , Gazin , C. , Naoe , T. , Chen , S. J. , Wang , Z. Y. and Chen , Z.In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl‐2 expression and modulation of PML‐RAR alpha/PML proteins . Blood , 88 , 1052 – 1061 ( 1996. ). [PubMed] [Google Scholar]
  • 23. ) Zhu , J. , Koken , M. H. , Quignon , F. , Chelbi‐Alix , M. K. , Degos , L. , Wang , Z. Y. , Chen , Z. and de The , H.Arsenicinduced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia . Proc. Natl. Acad. Sci. USA , 94 , 3978 – 3983 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. ) Sternsdorf , T. , Puccetti , E. , Jensen , K. , Hoelzer , D. , Will , H. , Ottmann , O. G. and Ruthardt , M.PIC‐1/SUMO‐1‐modified PML‐retinoic acid receptor α mediates arsenic trioxide‐induced apoptosis in acute promyelocytic leukemia . Mol. Cell. Biol. , 19 , 5170 – 5178 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. ) Fagioli , M. , Alcalay , M. , Tomassoni , L. , Ferrucci , P. F. , Mencarelli , A. , Riganelli , D. , Grignani , F. , Pozzan , T. , Nicoletti , I. , Grignani , F. and Pelicci , P. G.Cooperatio between the RINGB2 and coiled‐coil domains of PML is necessary for its effects on cell survival . Oncogene , 16 , 2905 – 2913 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Quignon , F. , De Bels , F. , Koken , M. , Feunteun , J. , Ameisen , J. C. and de The , H.PML induces a novel caspase‐independent death process . Nat. Genet. , 20 , 259 – 265 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Wang , Z. G. , Delva , L. , Gaboli , M. , Rivi , R. , Giorgio , M. , Cordon‐Cardo , C. , Grosveld , F.and Pandolfi, P. P. Role of PML in cell growth and the retinoic acid pathway . Science , 279 , 1547 – 1551 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Wang , Z. G. , Ruggero , D. , Ronchetti , S. , Zhong , S. , Gaboli , M. , Rivi , R. and Pandolfi , P. P.PML is essential for multiple apoptotic pathways . Nat. Genet. , 20 , 266 – 272 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Borden , K. L. , CampbellDwyer , E. J. and Salvato , M. S.The promyelocytic leukemia protein PML has a pro‐apoptotic activity mediated through its RING domain . FEBS Lett. , 418 , 30 – 34 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES